CONTINUE TO SITE
OR WAIT null SECS
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB
“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.
In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.
